Table 2 Correlations between clinicopathological features and expressions of CAGE and ATG5 in pulmonary ADC with EGFR mutation.

From: Cancer/testis antigen CAGE mediates osimertinib resistance in non-small cell lung cancer cells and predicts poor prognosis in patients with pulmonary adenocarcinoma

Molecular parameter

CAGE expression (40)

ATG5 expression (100)

Negative n (%)

Positive n (%)

p

Negative n (%)

Positive n (%)

p

Sex

Male

14 (70.0)

6 (30.0)

0.644

16 (84.2)

3 (15.8)

0.368

Female

36 (64.3)

20 (35.7)

 

41 (70.7)

17 (29.3)

 

Age

 < 60

20 (62.5)

12 (37.5)

0.606

23 (71.9)

9 (28.1)

0.717

 ≥ 60

30 (68.2)

14 (31.8)

 

34 (75.6)

11 (24.4)

 

Smoking

Never

34 (63.0)

20 (37.0)

0.275

41 (73.2)

15 (26.8)

0.765

Ever

16 (76.2)

5 (23.8)

 

16 (80.0)

4 (20.0)

 

Tumor size

 < 3 cm

25 (67.6)

12 (32.4)

0.750

33 (86.8)

5 (13.2)

0.011

 ≥ 3 cm

25 (64.1)

14 (35.9)

 

24 (61.5)

15 (38.5)

 

LN metastasis

Negative

36 (73.5)

13 (26.5)

0.030

41 (83.7)

8 (16.3)

0.005

Positive

12 (48.0)

13 (52.0)

 

14 (53.8)

12 (46.2)

 

EGFR expression

Negative

24 (68.6)

11 (31.4)

0.637

30 (83.3)

6 (16.7)

0.081

Positive

26 (63.4)

15 (36.6)

 

27 (65.9)

14 (34.1)

 

HER2 expression

Negative

50 (66.7)

25 (33.3)

0.342

56 (73.7)

20 (26.3)

1.000

Positive

0 (0.0)

1 (100.0)

 

1 (100.0)

0 (0.0)

 

c-MET expression

Negative

36 (66.7)

18 (33.3)

0.492

41 (74.5)

14 (25.5)

0.604

Positive

11 (57.9)

8 (42.1)

 

13 (68.4)

6 (31.6)

 

MET amplification

Absent

20 (64.5)

11 (35.5)

0.848

26 (81.2)

6 (18.8)

0.736

Present

13 (61.9)

8 (38.1)

 

16 (76.2)

5 (23.8)

 
Back to article page